'%20id='ico-down'%20stroke='%23000000'%20stroke-width='1.5'%3e%3cg%20transform='translate(1092.250000,%20254.750000)'%3e%3cpolyline%20id='Path-2-Copy-4'%20transform='translate(5.500000,%202.750000)%20scale(1,%20-1)%20rotate(-180.000000)%20translate(-5.500000,%20-2.750000)%20'%20points='0%200%205.5%205.5%2011%200'%3e%3c/polyline%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
14 December 2007
MADRID – Spanish biopharmaceutical group Zeltia said yesterday it was planning to float its Neuropharma on the stock market at the end of next year or the beginning of 2009.
Neuropharma specialises in the treatment of neuro-degenerative illnesses. It launched clinical trials on humans at the start of this year for its treatment of Alzheimer’s.
In a presentation to analysts filed with the National Securities Commission (CNMV), Zeltia said it would seek permission to market its Yondelis compound for the treatment of ovarian cancer. Zeltia unit Pharmar got the go-ahead from the European authorities earlier this year to begin selling Yondelis for the treatment of soft tissue sarcoma, a very aggressive form of cancer that affects muscle, bones and blood vessel tissues.
[Copyright EL PAÍS, SL./ Adrián Soto 2007]
Subject: Spanish news